Indication
Stage IVB Differentiated Thyroid Gland Carcinoma
1 clinical trial
3 products
Clinical trial
Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid CancerStatus: Recruiting, Estimated PCD: 2024-10-30
Product
BinimetinibProduct
EncorafenibProduct
Nivolumab